NASDAQ: QCLS · Life Sciences · 3 alerts · CIK 1321834
Share price
$0.3210Close, Nov 16
Market cap
$2.77M
Shares outstanding
8.62MLatest SEC cover page
Sector
Life Sciences
Industry
In Vitro & In Vivo Diagnostic SubstancesSIC 2835
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Q/C Technologies, Inc. filings on SEC EDGAR ↗
Q/C Technologies reported a net loss of $11.3 million for the nine months ended September 30, 2026, driven by significant stock-based compensation and a $3.2 million impairment of a technology license. The company remains pre-revenue, with its accumulated deficit increasing to $155.9 million and total stockholders' equity declining to $16.1 million.
Q/C Technologies received a deficiency notice from Nasdaq on November 6, 2026, because its common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has 180 calendar days, or until May 5, 2027, to regain compliance with the minimum bid price requirement. If compliance is not regained, the company may be eligible for an additional 180-day period or face delisting.
Q/C Technologies appointed Dr. Yossef Ehrlichman as Chief Technology Officer and entered into an amended employment agreement. The agreement includes an annual base salary of $275,000 and a restricted stock award with a grant date fair market value of $250,000, subject to stockholder approval of a share reserve increase. Dr. Ehrlichman previously served as the company's Founding Manager of Photonic Integrated Circuit Development.